Haemonetics (HAE) Net Income towards Common Stockholders (2009 - 2026)

Haemonetics' Net Income towards Common Stockholders history runs 18 years deep, the most recent figure standing at -$20.1 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 134.75% year-over-year to -$20.1 million in Q1 2026; TTM through Mar 2026 was $97.3 million, a 41.95% decrease from a year earlier, with the FY2026 full-year figure at $97.3 million, down 41.97% from the prior year.
• Net Income towards Common Stockholders retreated to -$20.1 million in Q1 2026 per HAE's latest filing, from $44.7 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $58.0 million in Q1 2025 and bottomed at -$20.1 million in Q1 2026.
• The 5-year median for Net Income towards Common Stockholders is $33.1 million (2022), against an average of $29.5 million.
• Across the five-year window, Net Income towards Common Stockholders soared 546.27% in 2022 and sank 134.75% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $32.9 million in 2022, then retreated by 5.17% to $31.2 million in 2023, then gained by 20.09% to $37.5 million in 2024, then gained by 19.25% to $44.7 million in 2025, then plunged by 145.03% to -$20.1 million in 2026.
• Per Business Quant, the three latest HAE Net Income towards Common Stockholders figures stand at -$20.1 million (Q1 2026), $44.7 million (Q4 2025), and $38.7 million (Q3 2025).